Literature DB >> 11809925

Exploring the unique pharmacology of a novel opioid receptor, ZFOR1, using molecular modeling and the 'message-address' concept.

I J McFadyen1, T G Metzger, M G Paterlini, D M Ferguson.   

Abstract

Previous studies have probed the structural basis of ligand selectivity in the mu, delta and kappa opioid receptors through the application of molecular modeling techniques in concert with the 'message-address' concept. Here, this approach was used in an attempt to rationalize the unique pharmacological profile of a recently cloned novel opioid receptor, ZFOR1 (ZebraFish Opioid Receptor 1). Specifically, a model of the transmembrane domains of ZFOR1 was constructed and used to explore the binding modes of various prototypical opioid ligands. The results show that the 'message' portion of the binding pocket of ZFOR1 is highly conserved; hence, the binding modes of non-selective opioid ligands are well preserved. In contrast, a small number of variant residues at the extracellular end of the binding pocket, particularly Lys288 (VI:26) and Trp304 (VII:03), are shown to create adverse steric interactions with all delta and kappa selective ligands examined, thereby disrupting their binding modes. These results are consistent with, and serve as an explanation for, the observed pharmacology of this receptor, lending support to both the validity of the 'message-address' concept itself and to the use of molecular modeling approaches in its application.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11809925     DOI: 10.1093/protein/14.12.953

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  2 in total

1.  Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity.

Authors:  M Germana Paterlini
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

2.  A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function.

Authors:  Chris M Brasel; Gregory W Sawyer; Craig W Stevens
Journal:  Eur J Pharmacol       Date:  2008-10-09       Impact factor: 4.432

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.